Member Info for allah4uk

NCYT regularly gave sales updates after they obtained the CE mark.

People complained because they never gave specific numbers for the US, mostly due to NDA, and rightfully people weren't too happy with that. But at least the company made general comments on that market.

At some point NCYT decided to stop dropping frequent sales RNS, which was met with some regret, but the announcement of landmark contracts has shut people up.

The morale of the story is that a company may afford *not* to regularly report on its sales - but only after it has reassured its shareholders that it is effectively able to deliver on the commercial aspect.

And in that light, no, GDR isn't about to become NCYT Mk2. Not anytime soon.
It had the potential to, but the company's engineers and shareholders were let down by the management.

GDR will get sales, but won't achieve its full potential until it has gotten rid of its current CEO.

Llyod your lack of critical thinking is pretty boring. What's even more concerning is that there are many people of your kind round here (such as Clark who posted right after you), very prone to cognitive bias and thus unfit for investing in risky stocks.

That CE mark doesn't seem to have helped much, meanwhile it could have been put to better use in Europe.

If no sales were ever intended in Europe, why apply for a CE mark then ? Wasn't that a waste of time and money ?

Raging rampers sadly omit the fact that approvals have been gained in Europe, but strangely no sales have been reported on this vast continent.

The product is probably good, the problems lie in the management and in blind faith.

The situation really is simple to apprehend.

GDR announced its coronavirus test on 22 May.

Back then the company wrote :
"Following CE-IVD marking, the Company can commence commercial sales in the UK and across the EU immediately. The Company will now begin distribution to potential customers for initial clinical evaluations, and aims to record first commercial sales in June."

Five (!) months later, there has been no announcement as to the outcome of these targeted sales outside of the UK (because, just to be nice, let's pretend that they totally aren't interested in their home market).

There are two possible reasons behind this sorely missed sales RNS, and both highlight a certain lack of skills on the part of the CEO.

Option 1 : GDR made practically zero sales and so couldn't release an RNS => commercial incompetence.

Option 2 : GDR made substantial sales but didn't bother releasing an RNS => investors' relationship incompetence.

It beggars belief that inverstors who've been blatantly failed by that person continue to defend him, and it's alarming to read their pro-failure ramping, but from the angle of the infamous cognitive dissonance, that makes total sense.

Very true Jay, DB is such a basket case, not even God can help him !

More damage control from Lloyd and his pal, that's both boring and appalling.

May they eventually find the faith to face the truth about GDR's questionable management.

There is no defamation here, merely an acknowledgement of that person's failure in his capacity as a CEO.

He might be a nice bloke on a personal level - but nicety isn't what shareholders are after. And I very much doubt that his engineers are happy to see their hard work going to waste, either.

That news reiterates the unique incompetence of GDR's CEO, who's successfuly squandered the advantage he once had over the competition.

It's indeed useful for newbies, who are thus able to witness a real world application of the concept of Opportunity Cost .

So are you Lloyd, so are you.

May Santa drop a Sales RNS under your Christmas tree.

Coping mechanism in full swing yet again. Denying reality and lashing out at contradictory evidence is so much easier than admitting one's failings.

Horrible C's... I agree : raging Chimps hitting hard at the wall of reality.

Worry not - even if the incompetent Tories don't hop onto the preventative treatment train, Blighty is but a Small Island in a Big Big World. More enlightened gubmints will be willing to invest in the safety of their citizens.

Magsy18 : opportunity cost is a legitimate concern.

GDR's SP should eventually shoot up (if RNS-worthy sales are finally announced) - but I'm not sure it'll be enough to make up for the potential gains that'd have been lost due to the long, long wait incurred by GDR's Dither & Delay strategy.

Dither and Delay (tm), they have learned well from the Tories.

longtermholder14 :

"The tests which are currently in the market place are no where near accurate enough."
This blatant lie is a coping mechanism of the highest order.

"no wonder they've steered away from the UK"
Nah, it's more likely the management was too incompetent to sell in their home market.

Worry not OP, for AVCT is not the worst in this regard.

GDR has sold jack sh*t... yet they don't even have the excuse of trying to roll out a revolutionary technology. That's pretty sad.

The usual waffle then.

I meant to say that in both case there's an issue with promotion, although not to the same extent (fortunately for YGEN).